Predicted Trait | |
Reported Trait | Alzheimer's disease |
Mapped Trait(s) | Alzheimer disease (MONDO_0004975) |
Score Construction | |
PGS Name | ad_noapoe_0.1_pgs |
Development Method | |
Name | PRSice-2 |
Parameters | Excluded variants in the APOE region (chr 19, GRCh37 coordinates 44,912,079 to 45,912,079). clump-kb = 250, p= 1, r2 = 0.001, threshold = 0.1 |
Variants | |
Original Genome Build | GRCh37 |
Number of Variants | 8,858 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000527 |
Citation (link to publication) | Green RE et al. Alzheimers Res Ther (2023) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 100% 63,926 individuals (100%) |
PGS Evaluation | Not Reported: 100% 1 Sample Sets |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST007511 Europe PMC: 30820047 |
63,926 individuals | European | NR |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM020223 | PSS011307| Ancestry Not Reported| 1,638 individuals |
PGP000527 | Green RE et al. Alzheimers Res Ther (2023) |
Reported Trait: Alzheimer's disease biomarker (linolenate (18:3n3 or 3n6)) | β: -0.05431 [-0.103025695, -0.005590157] | — | — | — | — |
PPM020222 | PSS011307| Ancestry Not Reported| 1,638 individuals |
PGP000527 | Green RE et al. Alzheimers Res Ther (2023) |
Reported Trait: Alzheimer's disease biomarker (docosapentaenoate (DPA; 22:5n3)) | β: -0.07733 [-0.125825807, -0.028839878] | — | — | — | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS011307 | — | — | 1,638 individuals, 49.6 % Male samples |
— | Not reported | — | NSHD | Outcomes tested were metabolite levels generated by Metabolon Inc, and metabolite modules generated using this data. All outcome (metabolite) data were collected at the 60-64 wave of the NSHD. |